Ventricular bigeminy associated with voriconazole, methadone and esomeprazole

Int J Clin Pharm. 2011 Dec;33(6):905-8. doi: 10.1007/s11096-011-9581-3. Epub 2011 Nov 23.

Abstract

Case: We report a case of ventricular bigeminy with concomitant administration of methadone, voriconazole and esomeprazole in a Caucasian woman aged 26 with acute lymphoblastic leukaemia. Plasma concentrations of voriconazole and methadone were high, 12.4 mg/l (therapeutic range: 1-4 mg/l) and 1.6 mg/l (therapeutic range: 0.2-0.4 mg/l), respectively. In the absence of esomeprazole, no more episode of cardiac arrhythmia occurred and 7 days after, methadone plasma concentration fell at 0.57 ml/l while voriconazole concentration was at 5.5 mg/l. We speculate that a pharmacokinetic interaction between methadone and voriconazole was amplified by the addition of esomeprazole. This led to the large increase of the plasma concentration of methadone and was potentially responsible for its cardiac toxicity.

Conclusion: Physicians should be aware of the potential interaction between voriconazole, esomeprazole and methadone leading to arrhythmia. The inhibitory potential of voriconazole is possibly increased by esomeprazole.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / pharmacokinetics
  • Analgesics, Opioid / therapeutic use
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / therapeutic use
  • Arrhythmias, Cardiac / chemically induced*
  • Arrhythmias, Cardiac / physiopathology
  • Drug Interactions
  • Esomeprazole / administration & dosage
  • Esomeprazole / adverse effects*
  • Esomeprazole / therapeutic use
  • Female
  • Humans
  • Methadone / adverse effects*
  • Methadone / pharmacokinetics
  • Methadone / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Proton Pump Inhibitors / administration & dosage
  • Proton Pump Inhibitors / adverse effects*
  • Proton Pump Inhibitors / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use
  • Triazoles / adverse effects*
  • Triazoles / pharmacokinetics
  • Triazoles / therapeutic use
  • Ventricular Dysfunction / chemically induced
  • Ventricular Dysfunction / physiopathology
  • Voriconazole

Substances

  • Analgesics, Opioid
  • Antifungal Agents
  • Proton Pump Inhibitors
  • Pyrimidines
  • Triazoles
  • Voriconazole
  • Esomeprazole
  • Methadone